|
|
|
|
||
So the trial was a failure? "According to EvaluatePharma’s sellside consensus, TransCon hGH is forecast to have sales of $1.2bn in 2024, compared with just $16m for somatrogon." If it's anyway accurate the word must have got out that PFE will not file and that's why they desperate for cash. https://www.evaluate.com/vantage/articles/news/snippets/pfizers-growth-hormone-falls-short |
return to message board, top of board |